Skip to content

Opening book details…

Can I read Imatinib treatment inhibit IL-6, IL-8, NF-KB and AP-1 production and modulate intracellular calcium in CML patients on EtoBox?

Imatinib treatment inhibit IL-6, IL-8, NF-KB and AP-1 production and modulate intracellular calcium in CML patients by Roberto Ciarcia; Maria Teresa Vitiello; Massimiliano Galdiero; Carmen Pacilio; Valentina Iovane; Danila d'Angelo; David Pagnini; Giuseppe Caparrotti; Daniele Conti; Valentina Tomei; Salvatore Florio; Antonio Giordano is a Biochemistry, Genetics and Molecular Biology article available to read on EtoBox.

What is Imatinib treatment inhibit IL-6, IL-8, NF-KB and AP-1 production and modulate intracellular calcium in CML patients about?

## Abstract Imatinib (IM) is considered the gold standard for chronic myeloid leukemia (CML) treatment, although resistance is emerging as a significant problem. The proinflammatory cytokines interleukin‐6 (IL‐6) and interleukin‐8 (IL‐8) play an important role in cell proliferation, survival, and resistance to glucocorticoid‐mediated cell death. Several transcription factors such as NF‐KB and AP‐1 are activated in response to physiopathological increases and modulation of intracellular calcium levels. Our previous study demonstrated that lymphocytes from CML patients showed dysregulated calcium homeostasis and oxidative stress. Alteration in ionized calcium concentration in the cytosol has been implicated in the initiation of secretion, contraction, and cell proliferation. In this study, we hypothesized that IL‐6, IL‐8, NF‐kB, AP‐1, and intracellular calcium may be used as selective and prognostic factors to address the follow‐up in CML patients treated with imatinib. Our results demonstrated a significant down‐regulation in IL‐6 and IL‐8 release as well as NF‐kB and AP‐1 activation in lymphomonocytes from Imatinib‐treated patients, compared to samples from untreated patients. In p

Who reads Imatinib treatment inhibit IL-6, IL-8, NF-KB and AP-1 production and modulate intracellular calcium in CML patients?

It is typically read by researchers, students, and practitioners in Biochemistry, Genetics and Molecular Biology.

Author
Roberto Ciarcia; Maria Teresa Vitiello; Massimiliano Galdiero; Carmen Pacilio; Valentina Iovane; Danila d'Angelo; David Pagnini; Giuseppe Caparrotti; Daniele Conti; Valentina Tomei; Salvatore Florio; Antonio Giordano
Publisher
John Wiley and Sons; Wiley (John Wiley & Sons); John Wiley & Sons Inc.; Wiley (ISSN 0021-9541)
Published
2012
Language
EN
Field
Biochemistry, Genetics and Molecular Biology (Life Sciences)

More by Roberto Ciarcia; Maria Teresa Vitiello; Massimiliano Galdiero; Carmen Pacilio; Valentina Iovane; Danila d'Angelo; David Pagnini; Giuseppe Caparrotti; Daniele Conti; Valentina Tomei; Salvatore Florio; Antonio Giordano

Browse all works by Roberto Ciarcia; Maria Teresa Vitiello; Massimiliano Galdiero; Carmen Pacilio; Valentina Iovane; Danila d'Angelo; David Pagnini; Giuseppe Caparrotti; Daniele Conti; Valentina Tomei; Salvatore Florio; Antonio Giordano